Sufficient ointment should be applied onto the affected and surrounding skin areas twice a day, in the morning and evening for 2 weeks in tinea cruris and tinea corporis and for 4 weeks in tinea pedis.

This preparation is contraindicated in those patients with history of sensitivity to any of its components or to other corticosteroids or imidazoles.

If sensitization or irritation develops with the use of the ointment, treatment should be discontinued. Systemic absorption of topical corticosteroides can produce reversible hypothalmic-pituitary-adrenal (HPA) axis suppression. If HPA axis suppression is noted, an attempt should be made to withdraw the drug or to reduce the frequency of application. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their large skin surface to body mass ratios.

Rarely seen adverse reactions include : burning, rash, edema, pruritus and urticaria of skin.

No information is available.

Use in Pregnancy & Lactation: Only be used in pregnancy if the benefit justifies the potential risk to the fetus. It is not known whether the component of this preparation are excreted in human milk and therefore caution should be exercised when treating nursing mother.
Use in Children: The safety and effectiveness of this preparation has not been established in children below the age of 12.

Packing: Aristobet-CL: Each tube contains 15 g Ointment.